Festival of Biologics 2026 has ended. This guide stays up as the record of who was there. Next: Festival of Biologics 2027, Oct 5–7, 2027 in Basel
Peptides and GLP-1 drugs at Festival of Biologics 2026
Oct 13–15, 2026 Basel, Switzerland ~3k attendees Website
7 organizations at Festival of Biologics 2026 present work in peptides & GLP-1: 4 drug developers, 2 suppliers and service providers and 1 academic, government or non-profit body. Between them they bring 12 presentations to the program. Most represented: AstraZeneca, University College Dublin and Ironwood Pharmaceuticals. As of Sep 26, 2026.
| Organization | Festival of Biologics 2026 Attendance |
|---|---|
AstraZeneca Cambridge, United Kingdom | |
Talk Tue Oct 13 16:50 Optimizing recombinant protein expression workflows by leveraging automation and predictive models Ways to speed up making proteins in the lab by combining automated workflows with models that predict the best genetic code choices. Talk Tue Oct 13 17:50 Advancing Antibody Discovery Through Integrated single B-Cell Technologies How to find therapeutic antibodies by profiling individual immune B cells, and how computer predictions are combined with the laboratory work. Talk Wed Oct 14 12:30 Chair Wed Oct 14 16:45 Talk Wed Oct 14 16:50 Integrating AI/ML into Biologics Discovery: Design, Optimization, Developability, and Immunogenicity How AI supports biologic drug discovery, from designing molecules to predicting how easily they are made and whether the body attacks them. Talk Thu Oct 15 12:20 Talk Thu Oct 15 12:20 | |
University College Dublin Dublin, Ireland | |
Talk Wed Oct 14 17:10 Talk Thu Oct 15 12:00 New GLP-1R Biology: Agonists, Inverse Agonists & Beyond How ten peptides found by phage display turn on, turn down or otherwise change the GLP-1 receptor, and what that means for medicine. | |
IP Ironwood Pharmaceuticals Boston, MA | |
Gastrointestinal health company that markets the peptide drug linaclotide. | Talk Thu Oct 15 11:40 Analytical Strategy for Therapeutic Synthetic Peptides: From Development to Quality Control How to plan the tests that check synthetic peptide drugs, from early development through routine quality control, in line with regulator expectations. |
N Numaferm Düsseldorf, Germany | |
Biotech company producing peptides and proteins with its Numaswitch expression platform, including scarless GLP-1 analog manufacturing. | |
OB Oncosimis Biotech | |
AI-driven protein and peptide optimization, aiming to meet affinity and other goals with ten times fewer experimental variants, often in one round. | Booth Exhibiting at Booth S4 |
Develops cell-penetrating peptide drugs that disrupt intracellular protein interactions, with oncology candidates in clinical development. | Booth Exhibiting (no floor booth listed) |
Find buyers in peptides & GLP-1
Tell us what you sell and we’ll find the people at organizations working on peptides & GLP-1 most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Browse Festival of Biologics 2026 by
- Antibody & protein engineering 67
- AI & computational design 38
- Bispecifics & multispecifics 13
- ADCs & armed antibodies 18
- Immunotherapy & oncology 44
- Cell & gene therapy 28
- Therapeutic vaccines 13
- Peptides & GLP-1 7
- Bioprocessing & manufacturing 87
- CMC, formulation & analytics 58
- Clinical development 45
- Regulation & market access 40
Not affiliated with or endorsed by the Festival of Biologics or its organizers. Submit a correction